

30 Nov 2021 | Analysis

APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

Innovation, Vaccines A Key Focus

by Ian Haydock

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.

The Asia-based content team for *Scrip* and the *Pink Sheet* dissect the major events shaping the regional pharma industry over the past few months, including and beyond the ongoing coronavirus pandemic.

Join Brian Yang in Beijing, Dexter Yan in Shanghai, Anju Ghangurde and Vibha Ravi in Mumbai, Jung Won Shin in Seoul and Ian Haydock in Tokyo for a top-line overview of key developments, including the impact of China's "dual circulation" policy, how Chinese firms are looking more inwards for innovation, India's moves to boost original pharma R&D, vaccine progress in India, South Korea's robust biopharma funding trends, and Japan's corporate and regulatory progress amid the pandemic.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

[Click here to explore this interactive content online](#) ✨

Intro/China Dual Circulation Policy

Brian looks at China's move to a new dual circulation macro-economic policy and its likely impact.

China Pricing And Corporate Development (Starts 11'15")

Dexter breaks down recent pricing developments and observes how more Chinese firms are beginning to look inward to access emerging innovation.

India's New R&D Support Policy Plans (Starts 17'10")

Anju talks about new moves in India to support innovative R&D and the reasons behind these.

India's Vaccine Story And Recent COVID-19 Developments (Starts 23'44")

Vibha provides context around India's historical vaccine capabilities and assesses how these have played out amid the pandemic.

South Korea Sees Healthy Biopharma Funding (Starts 30'55")

Jung Won discusses recent trends around funding in-flows to the sector, which remain strong despite the pandemic.

Recent Policy And Regulatory Trends in Japan (Starts 34'16")

Ian gives an overview of the policy and corporate impact of the pandemic and how this is driving change.

Selected Related Stories

(Also see "[Pharma Will Need To Embrace More Inward-Looking China](#)" - Scrip, 24 Nov, 2021.)

(Also see "[Chinese Firms Look Inward To Access Innovation](#)" - Scrip, 23 Nov, 2021.)

(Also see "[India's 'Thousand Talents' Moment And Models To Shift Gears In R&D](#)" - Scrip, 24 Nov, 2021.)

(Also see "[Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe](#)" - Scrip, 25 Oct, 2021.)

(Also see "[Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021](#)" - Scrip, 23 Nov, 2021.)

(Also see "[Coronavirus Update: Japan Approves Sotrovimab](#)" - Scrip, 30 Sep, 2021.)

